Blake Borgeson - Sep 5, 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Director
Signature: /s/ Jonathan Golightly, attorney-in-fact
Stock symbol: RXRX
Transactions as of: Sep 5, 2023
Transactions value $: -$78,136
Form type: 4
Date filed: 9/7/2023, 08:02 PM
Previous filing: Aug 24, 2023
Next filing: Sep 21, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Sale	-$78.1K	-8.89K	-0.12%	$8.79	7.45M	Sep 5, 2023	Direct	F1, F2

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022.
F2	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $8.61 to $9.15 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.